Cognitive and behavioral dysfunction in Parkinson's disease: neurochemical and clinicopathological contributions.
about
Preservation of function in Parkinson's disease: what's learning got to do with it?Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?Parkinson Disease and Dementia.Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson'The neural circuitry of executive functions in healthy subjects and Parkinson's diseaseMotor and Non-Motor Symptoms in Parkinson's Disease: Effects on Quality of Life.Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease.Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: an (11)C altropane positron emission tomography study.An examination of executive dysfunction associated with frontostriatal circuitry in Parkinson's disease.Parkinson's disease dementia: a neural networks perspective.Animal models of the non-motor features of Parkinson's disease.Impaired learning and memory in Pitx3 deficient aphakia mice: a genetic model for striatum-dependent cognitive symptoms in Parkinson's disease.Cognitive impairment in Parkinson's disease and dementia with lewy bodies: a spectrum of disease.Stem cell grafting improves both motor and cognitive impairments in a genetic model of Parkinson's disease, the aphakia (ak) mouse.Rivastigmine in Parkinson's disease dementia.Impairment of script comprehension in Lewy body spectrum disorders.Mild cognitive impairment in Parkinson disease: heterogenous mechanisms.Neuropsychological and physiological correlates of fatigue following traumatic brain injury.Depression in Parkinson's disease: the effectiveness and risk of pharmacotherapy. Clinical review.Long-lasting paracrine effects of human cord blood cells on damaged neocortex in an animal model of cerebral palsy.Diagnoses behind patients with hard-to-classify tremor and normal DaT-SPECT: a clinical follow up study.Influence of left versus right hemibody onset Parkinson's disease on cardiovascular control.Sentence processing in Lewy body spectrum disorder: the role of working memory.Ghrelin is neuroprotective in Parkinson's disease: molecular mechanisms of metabolic neuroprotection.Changes of brain gray matter structure in Parkinson's disease patients with dementiaA holistic analysis of relationships between executive function and memory in Parkinson's disease.Dementia and functional decline in patients with Parkinson's disease.Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial.Mood disturbances and cognitive functioning in Parkinson's disease: the effects of disease duration and side of onset of motor symptoms.Depressive symptoms in Parkinson disease correlate with impaired global and specific cognitive performance.Coping processes and health-related quality of life in Parkinson's disease.Frontotemporal Lobe Degeneration as Origin of Scans Without Evidence of Dopaminergic Deficit.Late (Complicated) Parkinson's Disease
P2860
Q26853387-C39AC1F4-9D53-498E-B995-602CD3580D31Q27021464-F337DCB1-1CC2-4483-BF3D-47B2CBF837D8Q30248574-6643368E-7F35-4AB6-933F-E6E03044DB58Q33260251-3F9A7ABF-83BA-42D6-A37B-2B681A51AAD9Q33490981-1437F001-EAE9-442C-AFA9-6C562DFFCEEDQ33854899-9EA6D5B1-739D-4442-8900-72EC3683F288Q34181738-7771EB79-F64D-4501-86D0-3789A3FF7549Q34576144-B9C31693-6008-4953-BDEE-EA2119F07956Q35684460-28749A58-1BDA-4D45-BEC9-8DE4996F9F55Q36186763-191EEEBE-D65D-4402-B354-954BB0A2814CQ36235578-AB5D9E8C-200C-4F77-BC4A-C4FA802FE685Q36996302-D8D36510-4681-4F1D-ADB3-567A44876DBEQ37039444-2BC50236-93C7-43FC-8C73-EC47C0409931Q37118996-49BE860A-598A-4C39-BD52-F55C028975DDQ37556550-F602E908-F07A-436A-9F59-249C39D0544AQ37614628-13487ACD-78D9-45FE-A51D-2212A42BDAD2Q37986572-41452A70-B5CF-4769-BFE3-99C70A6A0981Q38190625-D6E24ABE-6322-4055-9118-621238142D4AQ38265929-522A454E-1F03-4EA5-A5A4-5567C9D2127AQ38463311-C3430730-416E-49D3-B4A5-17F899125C5AQ38642358-E8B7AB78-CDFF-4811-8171-14ED2C69E259Q39889917-741D683F-3D76-4D1A-BC56-8F2514E44EEEQ40643330-A5E8E041-D3F1-4DE6-A800-049BCBBF8B95Q41361484-AE53E70D-E17F-465E-AD9A-099D1DDB5CFAQ42744489-1DBB5999-AB66-419D-9625-4F2657528166Q43846283-B1F12566-7D1C-4C50-8EE7-61BE578D4CD8Q46352438-2EB17FAB-572E-49D6-BCF0-44B44C9DC576Q47958506-6DA349CD-183F-4656-98C0-AD575A3F8015Q48539794-8301617B-FE2C-4FCA-AA89-B4039ADE4BF8Q48621833-6787365E-F8D8-43DD-9D9B-935DFE070A18Q49131297-CD6069A6-2FCA-4971-9BE4-6E31A6C21BBCQ55010173-D4A81330-0EC8-4EFD-B553-635E58B3D2A1Q58870320-BFF462FB-DBD7-4872-AD98-3D3FFDDFD6D4
P2860
Cognitive and behavioral dysfunction in Parkinson's disease: neurochemical and clinicopathological contributions.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Cognitive and behavioral dysfu ...... icopathological contributions.
@ast
Cognitive and behavioral dysfu ...... icopathological contributions.
@en
type
label
Cognitive and behavioral dysfu ...... icopathological contributions.
@ast
Cognitive and behavioral dysfu ...... icopathological contributions.
@en
prefLabel
Cognitive and behavioral dysfu ...... icopathological contributions.
@ast
Cognitive and behavioral dysfu ...... icopathological contributions.
@en
P2093
P1476
Cognitive and behavioral dysfu ...... icopathological contributions.
@en
P2093
D J Zgaljardic
P2888
P304
P356
10.1007/S00702-004-0178-Z
P577
2004-07-07T00:00:00Z